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Abstract
Background: Innovative models of care are required to cope with the ever-increasing number of patients on antiretroviral
therapy in the most affected countries. This study, in Khayelitsha, South Africa, evaluates the effectiveness of a group-based
model of care run predominantly by non-clinical staff in retaining patients in care and maintaining adherence.
Methods and Findings: Participation in ‘‘adherence clubs’’ was offered to adults who had been on ART for at least 18
months, had a current CD4 count .200 cells/ml and were virologically suppressed. Embedded in an ongoing cohort study,
we compared loss to care and virologic rebound in patients receiving the intervention with patients attending routine
nurse-led care from November 2007 to February 2011. We used inverse probability weighting to estimate the intention-to-
treat effect of adherence club participation, adjusted for measured baseline and time-varying confounders. The principal
outcome was the combination of death or loss to follow-up. The secondary outcome was virologic rebound in patients who
were virologically suppressed at study entry. Of 2829 patients on ART for .18 months with a CD4 count above 200 cells/ml,
502 accepted club participation. At the end of the study, 97% of club patients remained in care compared with 85% of other
patients. In adjusted analyses club participation reduced loss-to-care by 57% (hazard ratio [HR] 0.43, 95% CI=0.21–0.91) and
virologic rebound in patients who were initially suppressed by 67% (HR 0.33, 95% CI=0.16–0.67).
Discussion: Patient adherence groups were found to be an effective model for improving retention and documented
virologic suppression for stable patients in long term ART care. Out-of-clinic group-based models facilitated by non-clinical
staff are a promising approach to assist in the long-term management of people on ART in high burden low or middle-
income settings.
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Introduction
Retaining patients in lifelong HIV care is a major challenge in
many countries in sub-Saharan Africa, where antiretroviral
treatment (ART) has been rapidly scaled up to some 5 million
people as of the end of 2010. [1] In recent years in South Africa,
an increasing proportion of patients on ART are being lost to
follow-up (LTF) as overall the numbers on treatment increase. [2]
Although up to a third of adult patients lost to care are estimated
to have died, the majority are alive: without treatment, they are at
increased risk of morbidity and mortality. [3].
Decentralization of services and task-shifting aspects of care to
nurses and non-clinical staff, including patients, has been found to
be feasible with good clinical outcomes.[4–12] However, such
approaches are reaching their limits as increasing numbers of
patients are initiated on ART. Accessible and flexible ART
services that differentiate between the needs of clinically ill patients
starting ART, and clinically stable patients who have been on
ART for some time, have been suggested as important strategies
for maintaining and improving retention and quality of care. [13].
Patient support groups have long been recognized as an
important adjunct to clinical care that encouraged retention and
PLOS ONE | www.plosone.org 1 February 2013 | Volume 8 | Issue 2 | e56088adherence. [14] The key evolution in the re-emergence of patient
groups is that they are now seen as an essential mechanism of
service delivery, including dispensing of ART and symptom
screening, and a means of decongesting formal health services,
rather than being purely an adherence adjunct. While encourag-
ing outcomes from these programs have been described, [7] they
have yet to be formally evaluated against more clinically intensive
models of care.
The number of people starting and retained on ART had
progressively increased between 2001 and 2007 in a large urban
ART clinic in Khayelitsha (Ubuntu Clinic), Cape Town, leading
to overcrowding, longer waiting times during visits, and less time
for counseling and clinical care of poorly adherent and newly
enrolling patients, and for tracing of patients lost to follow-up. In
response, in November 2007, patients stable on ART for at least
18 months or longer were offered voluntary participation in
‘‘adherence clubs’’ of 15–30 patients, which convened every two
months facilitated by trained counselors, aiming to free up
clinicians, decongest services and improve retention in and care
and adherence.
This study evaluated the effectiveness of adherence clubs
compared to traditional clinic-based care in maintaining or
improving long-term retention-in-care and virologic suppression.
Methods
Type of Study
We developed a retrospective observational evaluation of
adherence clubs. Accordingly, we built a Marginal Structural
Model (MSM) using Inverse Probability of Treatment Weighting
(IPTW) to estimate the intention-to-treat effect of adherence club
participation. The analytical approach was developed specifically
to address the obvious confounding bias whereby patients who
were already doing well were more likely to be offered club
participation. In the weighted analysis, club participation at any
time following the start of the study was rendered independent of
measured potential confounders. The study was nested within an
ongoing cohort study of routine ART outcomes in Khayelitsha,
Cape Town approved by the Human Research Ethics Committee
of the University of Cape Town. [3] Individual patient consent
was not needed, consistent with the South African Medical
Research Council’s Guidelines on Ethics for Medical Research
and the Declaration of Helsinki. Because this was a retrospective
analysis of routine clinical service records, no additional data
collection or procedures were undertaken from or on patients, all
patient information was entered anonymously into the database
using coded identification numbers, and no information that could
reveal patient identity was entered into the database.
Setting
ART was first offered in Khayelitsha in 2001 at three
community health centers serving an estimated population of
400,000. In 2011, over 20,000 adults and children had started
ART in the sub-district. The clinical protocols have been closely
aligned with international and national guidelines since inception.
At the time that the adherence clubs were first introduced, the
first-line regimen comprised stavudine, lamivudine and nevirapine
or efavirenz, and patients received twice-yearly viral load and
CD4 count monitoring. In a national guideline revision in April
2010 tenofovir replaced stavudine in the starting regimen, and
viral load and CD4 count monitoring was reduced to annually
beyond the first year on ART. [15] Historically, the majority of
consultations have been with nurses, while doctors have been
available to see very ill patients or receive referrals. Given the large
patient load of several thousand patients on ART, patients do not
consistently see the same practitioner from visit to visit. Facility-
based lay counselors have provided structured patient preparation
and adherence training at ART initiation and when adherence
challenges have been identified. Home visits and patient support
groups in addition to routine clinical care were a feature of the
program in the first three years, but were not available to the
majority of patients subsequently.
Adherence Clubs
Adherence clubs were piloted in late 2007 at the largest of the
community health centers (Ubuntu Clinic) to reduce the burden
on health services by shifting consultations and medicine
collections for stable patients to ‘‘clubs’’. These groups are
facilitated by non-clinical staff (counselors), who have previously
been trained in facility-based patient preparation and support, and
who receive additional training and mentoring. The meeting times
are scheduled outside of busy clinic times, and consequently are
more convenient for patients with much shorter waiting times.
The resulting decongestion of the clinic allows nurses to spend
more time initiating new patients on ART or with ill patients or
those experiencing difficulties.
Participation is offered to clinically stable adult patients who
have been on ART for at least 18 months. Guidelines further
recommend that patients should have had a CD4 count of more
than 200 cells/ml in the previous six months and have had
sustained viral load suppression. Groups of 15 to 30 patients are
formed and convene at the clinics during quiet times such as the
early mornings or afternoons. Medicines are pre-packaged for
each participant and brought to the group by a counselor who
weighs the patients and administers a symptom-based general
health assessment. Any patients reporting symptoms suggestive of
illness, adverse drug effects or who have weight loss are referred
back to the clinic to be assessed by a nurse. The counselor or
experienced patients lead short group discussions on a range of
health and other topics requested by the club participants. A nurse
attends these groups annually to draw blood for viral load and
CD4 count testing.
As adherence clubs was a pilot, only some of the stable patients
were offered participation, based on the clinician’s enthusiasm for
the model, and the opening of new clubs: 20 clubs were established
during the pilot. The determination of which stable patients were
enrolled into the clubs was therefore largely driven by service
factors as opposed to patient factors. Although not formally
documented, most patients with the option to transition to club-
based care took up this option due to the prospect of much less
time spent waiting for medicines.
Participants and Data Management
Data were extracted from the electronic medical record system
used in the HIV clinics, which was updated daily by data capturers
from structured clinical records completed by clinicians or from
club registers completed by the club facilitators. Rule-based
consistency assessments were used to identify specific patients and
data elements for review by quality assurance staff.
Following the inclusion criteria that clinicians were using to
offer club participation, we restricted the study to adult patients
($18 years old) who had been on ART for at least 18 months
when the pilot started, or who reached 18 months on ART during
the study period, and who’s most recent CD4 count was above
200 cells/ml. Patients entered the analysis at their first eligible visit
after November 1
st, 2007 and exited at the date of outcome, date
of censoring from follow-up or February 28
th, 2011.
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The principal outcome was a combined outcome of time to
either death or LTF. LTF was defined as not having any contact
with the service in the six months following the analysis closure
(between February 28
th and August 31
st 2011), and was de-
termined to have happened at the date of the last contact with the
service. Limited to patients who were virologically suppressed at
study entry, the secondary outcome was the time to the first
virologic rebound (.400 copies/mL).
The primary exposure/outcome relationships and variables
considered a priori to be potential confounders are outlined in
a causal diagram (Figure 1). These include age, gender, duration
on ART and World Health Organization (WHO) clinical stage
measured at study entry; CD4 count measured at ART initiation,
study entry, at any given time (t), and t-6 months; and viral load
suppression measured at study entry and at t.
Statistical Analysis
We summarized patient characteristics as percentages for
categorical variables and medians and interquartile ranges (IQR)
for continuous variables. We computed crude rates for each
outcome by patient characteristics at study entry, with 95%
Poisson confidence intervals.
For each outcome, we used an weighted pooled logistic
regression model to estimate the hazard ratio (HR) of club
participation versus routine clinic-based care, including as
covariates a time-varying indicator for history of club partici-
pation, month of follow-up (cubic splines with knots at the 5th,
25th, 50th, 75th and 95th percentiles) [16] and the baseline
covariates (age in years, gender, CD4 at ART start and study
entry per 100 cells/ml, Viral load suppression [,400 copies/ml]
at study entry, duration on ART in months and WHO clinical
stage). We used robust variance estimators.[17–19] The pooled
logistic model closely approximates the Hazard Ratios because
the probability of events occurring in any given month is small.
[20,21].
To estimate the inverse probability weights, we fitted a pooled
logistic regression model for first participation in an adherence
club. The model included month of follow-up, and the baseline
and time-varying covariates (current CD4 count per 100 cells/
ml, six month lagged CD4 count per 100 cells/ml and current
viral load suppression ,400 copies/ml). We used the predicted
probabilities of club participation to compute the denominator
of the IPTWs. The weights were then stabilized as previously
described. [20] For the secondary outcome, the final stabilized
weight included the probability of being uncensored by LTF.
Patients received a weight of one once they joined an adherence
club, and were assumed to remain part of the club until the end of
the study, akin to intention-to-treat analyses of randomized trials.
The weighted analysis created a statistical pseudo-population in
which the probability of entering an adherence club in each month
was unrelated to the measured CD4 cell count or viral load, thus
controlling for time-dependent confounders. [21] In order to show
the magnitude of the measured time-varying confounding we
compared the weighted hazard ratios for club participation to
unweighted estimates for both outcomes, both adjusted for co-
variates at study entry.
Finally, we explored the sensitivity of our estimates to
alternative models specifications (categorizing continuous variables
and including selected interaction terms) and truncation of the
IPTWs. All analyses were performed with Stata v.12.
Figure 1. A directed acyclic graph representing the causal relationships between adherence club participation, outcomes, baseline
and time-updated covariates.
doi:10.1371/journal.pone.0056088.g001
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Of the 2829 individuals followed up for 8821 patient years (py),
the median age of patients was 33 (IQR 29–39) years, and 71%
were women (Table 1). Patients entered the study after a median
43 (IQR 28–61) months on ART, and with a median CD4 count
of 202 cells/ml. The majority (88%) were virologically suppressed
at study entry. Club participation was offered and accepted by 502
patients (Figure 2) who enrolled a median 8 (IQR 7–10) months
after study entry, contributing 1273 py of follow-up. The
frequency of available virologic monitoring was similar between
club and other patients, averaging at least one test per year (Table
S1).
By the end of the study, 12.8% of patients were LTF or had died
(323 LTF and 40 deaths), and 9.0% had virologic rebound. Both
outcomes were less frequent for patients participating in the clubs
(29.8 vs 116.8 per 1000 py for LTF/death, crude rate ratio [RR]
0.25, 95% CI 0.14–0.41 and 31.8 vs 90.4 per 1000 py for virologic
rebound, RR 0.35, 95% CI 0.31–0.40, Table 1).
Overall, patients with lower CD4 counts at study entry, viremia
and clinical stage III/IV had higher crude rates of death or LTF,
but this risk was higher in patients not enrolled in clubs. Patients in
normal clinic-based care who were ,25 years old and who
entered the study with CD4 counts ,50 cells/ml had the highest
rates of death or LTF (192.8 and 254 per 1000 py respectively,
Table 1).
Virologic rebound was similarly high in patients ,25 years not
participating in a club (151.4 per 1000 py). Longer durations on
ART were associated with higher rates of virologic rebound, but
lower rates of death or LTF (Table 1).
Club participation was strongly associated with virologic
suppression (,400 copies/ml) at study entry (HR 3.1, 95% CI
1.3–7.6), and during subsequent follow-up (HR 4.5, 1.8–12.5,
Table 2). Patients with higher CD4 counts at study entry, an
increasing CD4 count during follow-up, women, and patients who
had been on ART for longer were also more likely to be enrolled
in a club. For the secondary analysis restricted to virologically
suppressed patients, the remaining associations with club partic-
ipation were comparable with the primary analysis (Table 2). The
estimated IPTWs had means of 1.06 and 1.05 respectively (Table
S2, Figure S1).
In the final weighted analysis (MSM) club participation reduced
death or loss to follow-up (HR=0.43, 95% CI 0.21–0.91) and
virologic rebound (HR=0.33, 95% CI 0.16–0.67). For both
outcomes, there was little evidence of time-varying confounding by
CD4 count and viral load, as weighted and unweighted models
resulted in similar estimates (Figure 3).These estimates were stable
in sensitivity analyses (Table S2).
Although other associations with each outcome were not
causally considered, when adjusting the final models for other
covariates at study entry, younger patients appeared at greater risk
of both outcomes as did patients with lower CD4 counts (Table
S3).
Discussion
During the study period the delivery of ART and adherence
support for stable adult patients on long-term ART in Khayelitsha
was shifted from individual consultations with nurses to group
consultations led by non-clinical staff. This model of care resulted
in improved retention on ART and decreased rates of virologic
rebound.
The imperative for simplified models of care for ART in high
burden countries is well established, [13] and is especially relevant
Figure 2. Patients included in the analysis, enrolment into clubs, and outcomes at the end of the study.
doi:10.1371/journal.pone.0056088.g002
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require even greater expansion of ART provision. There is now
a solid body of evidence demonstrating that task-shifting has been
successfully implemented in a variety of settings and models,
expanding access to care, improving or maintaining quality of care
or improving cost-effectiveness. [24] The majority of the studied
models have involved the shifting of key care tasks to less qualified
clinical staff or to non-clinical staff, but few have been based on
patient groups.
Currently there is an emerging interest in patient groups as
the vehicle of service delivery, and not just as an adherence
adjunct to care. [7] Administrative efficiency and decongestion
of services are key aspects of the model: patients can bypass
queues for collecting folders, waiting to see a practitioner, and
waiting for medicines, converting a consultation process that
previously could take an entire day into one that can be
completed within half an hour.
Table 1. Patients characteristics at study entry and crude rates of progression to death/loss to follow-up and virologic rebound by
club participation.
Event rates (per 1000 person-years, 95% CI)
Death/loss to follow-up Virologic rebound*
N (%) In club** Not in club N (%)* In club** Not in club
All patients combined 2829 29.8 (17.9–49.5) 116.9 (105.2–129.8) 2517 31.8 (18.8–53.6) 90.4 (79.1–103.4)
Age in years at study entry
,25 284 (10.0) 30.8 (4.3–218.6) 192.8 (149.4–248.9) 228 (9.1) 68.0 (17.0–271.9) 151.4 (106.5–215.3)
25–34 1397(49.4) 18.8 (7.8–45.3) 120.6 (104.0–139.9) 1234 (49.0) 34.9 (17.5–69.9) 97.5 (80.9–117.4)
35–44 841 (29.7) 30.1 (12.9–74.4) 82.1 (65.3–103.3) 778 (30.9) 20.8 (6.7–64.6) 72.4 (55.4–94.5)
$45 307 (10.9) 91.9 (34.5–244.9) 123.1 (90.6–167.2) 277 (11.0) 26.3 (3.7–186.5) 65.1 (41.0–103.4)
Median (IQR) 32.9 (28.5–39.0) 33.2 (28.7–39.3)
Gender
Male 831 (29.4) 41.5 (18.6–92.3) 123.1 (101.9–148.8) 749 (29.8) 7.8 (1.1–55.8) 75.2 (57.5–98.4)
Female 1997 (70.6) 25.1 (13.1–48.3) 114.3 (100.7–129.7) 1767 (70.2) 41.5 (24.1–71.5) 96.9 (83.1–113.2)
CD4 count (cells/ml) at ART start
,50 601 (21.2) 15.3 (3.8–61.0) 153.3 (124.6–188.4) 518 (20.6) 34.2 (12.8–91.3) 94.6 (69.9–128.1)
50–99 560 (19.8) 34.2 (12.8–91.2) 134.1 (107.3–167.7) 496 (19.7) 30.0 (9.6–93.0) 84.6 (61.6–116.3)
100–199 1276 (45.1) 37.8 (18.9–75.5) 100.8 (85.3–119.1) 1151 (45.4) 27.1 (11.3–65.1) 96.2 (79.5–116.4)
$200 392 (13.4) 23.3 (3.3–165.7) 96.0 (71.1–129.2) 352 (14.0) 51.1 (12.8–204.5) 75.4 (52.0–109.2)
Median (IQR) 121 (60–176) 124 (62–177)
CD4 count (cells/ml) at study
entry
,50 520 (18.4) – 254.2 (216.5–298.4) 426 (16.9) – 106.7 (79.7–142.9)
50–99 203 (7.2) – 101.3 (68.9–148.7) 166 (6.6) – 64.5 (37.4–110.9)
100–199 675 (23.9) 52.4 (7.4–372.0) 71.3 (55.3–91.7) 582 (23.1) 235.1 (75.8–728.8) 78.3 (59.8–102.5)
$200 1431 (50.6) 29.6 (17.5–49.9) 87.3 (72.6–105.0) 1343 (53.4) 26.3 (14.5–47.5) 96.6 (79.7–117.2)
Median (IQR) 202 (97–386) 215 (110–404)
Duration on ART in months at study entry
,24 510 (18.1) – 136.3 (109.9–168.9) 464 (18.4) – 47.9 (32.6–70.3)
25–48 1084 (38.3) 76.7 (19.2–306.9) 132.9 (114.3–154.5) 961 (38.2) – 90.6 (73.9–111.1)
.48 1235 (43.6) 27.3 (15.9–47.1) 87.2 (71.2–106.5) 1092 (43.4) 33.7 (19.9–56.9) 119.2 (97.5–145.7)
Median (IQR) 43.1 (28.0–61.1) 42.8 (27.7–60.9)
Virologic suppression at study entry
Yes 2501 (88.4) 28.6 (16.9–48.3) 110.6 (98.6–124.2) – – –
No 327 (11.6) 74.9 (10.5–531.5) 160.0 (124.1–205.9) – – –
WHO clinical stage at study entry
I/II 781 (27.6) 32.2 (10.4–100.3) 81.6 (64.7–102.8) 716 (28.5) 36.9 (11.9–114.4) 79.5 (61.6–102.7)
III/IV 2045 (72.4) 29.3 (16.6–51.5) 131.9 (117.2–148.4) 1789 (71.5) 30.6 (16.9–55.3) 95.6 (81.7–112.0)
*Restricted to patients who had virologic suppression at study entry, n=2517.
**Patients who went on to enrol in a club contributed analysis time to the ‘‘not in club’’ group until they were enrolled in the club. There is no single point in time where
characteristics of patients who enrol in clubs and other patients can be formally compared due to the progressive nature of club enrolment. Instead predictors of club
participation are presented in Table 2. Table 1 shows event rates since study entry to the outcome endpoint or censoring.
ART: Antiretroviral therapy; WHO: World Health Organization; CI: Confidence interval; IQR (inter-quartile range).
doi:10.1371/journal.pone.0056088.t001
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Improved retention in care might result due to the removal of
these and other structural barriers to care, [25,26] which are
inherently improved with out-of-clinic models. Patients may also
potentially take responsibility for tracing and linking group
members back to care when they miss visits, and arguably be
more successful at achieving this than facility staff. Finally the
group dynamic itself may be an important contributor as was
historically motivated. [14].
Table 2. Factors associated with adherence club enrolment.
Death or LTF Virologic rebound*
Covariates at study entry HR (95% CI)** P-value
{ HR (95% CI)** P-value
{
Age in years 1.00 (0.98–1.02) 0.733 1.00 (0.98–1.01) 0.718
Gender (males vs females) 0.75 (0.60–0.93) 0.010 0.72 (0.58–0.91) 0.006
CD4 count at ART start (per 100 cells/ml) 0.86 (0.76–0.96) 0.012 0.83 (0.73–0.94) 0.005
CD4 count at study entry (per 100 cells/ml) 1.85 (1.70–2.00) ,0.001 1.80 (1.65–1.95) ,0.001
Viral load suppression at study entry (,400 copies/ml) 3.06 (1.25–7.60) 0.016
Duration on ART (per 12 months) 1.52 (1.43–1.61) ,0.001 1.53 (1.43–1.62) ,0.001
WHO clinical stage (I/II vs III/IV) 0.85 (0.66–1.11) 0.214 0.86 (0.66–1.12) 0.281
Time-varying covariates
Current CD4 count (Per 100 cells/ml) 1.02 (0.94–1.09) 0.585 1.01 (0.93–1.09) 0.754
Six month lagged CD4 count (Per 100 cells/ml) 0.62 (0.57–0.68) ,0.001 0.64 (0.58–0.70) ,0.001
Current viral load ,400 copies/ml 4.46 (1.79–12.5) 0.001
*Restricted to patients who had virologic suppression at study entry, n=2517.
**Hazard ratios were derived from a pooled unweighted logistic regression model fit on the subsample of person-months of follow-up for which no club participation
had yet occurred through the previous months.
{P-value based on Wald test.
LTF: Loss to follow-up; ART: Antiretroviral therapy; WHO: World Health Organization; HR: Hazard Ratio; CI: Confidence interval.
doi:10.1371/journal.pone.0056088.t002
Figure 3. Estimated effect of club participation from unweighted and weighted Cox models. Weighted model with baseline covariates
estimates the parameters of a marginal structural model, adjusting for confounding due to measured time-dependent covariates.
doi:10.1371/journal.pone.0056088.g003
Reinforcing Retention on ART
PLOS ONE | www.plosone.org 6 February 2013 | Volume 8 | Issue 2 | e56088A previous descriptive evaluation of a patient-group-based
model of care in Mozambique reported 97.5% of patients retained
in self-forming patient groups, [7] which is similar to the
proportion retained in the adherence clubs in Khayelitsha.
Virologic Rebound
Virologic rebound was expectedly low in both groups due to the
restriction to stable patients, but was lower in the club model.
There is a strong association between virologic rebound and gaps
or delays in medication collection. [27] The ease of medicine
collection associated with club participation (patients collect pre-
packaged medications during the club) and strong incentives to
collect medicines at the time of scheduled club meetings could
reduce potential gaps in treatment collection. In routine facility-
based care the time spent at the facility sometimes precludes
patients from keeping appointments due to other commitments.
Although the main motivation for the adherence club model
was the need for more efficient care, the potential for the clubs to
function as peer support groups is an important consideration.
The value of support groups is widely argued, but the impact on
virologic outcomes has not been systematically assessed. [28].
Additional Findings
We have previously reported higher rates of loss to follow-up
and virologic failure in adolescents and young adults in the study
setting, [3,29] consistent with the findings when adjusting our
analyses by age, notwithstanding that the study was not explicitly
designed to assess these associations. These findings and the
specific challenges in supporting adolescents and young adults
have also been noted elsewhere. [30].
Strengths and Limitations of the Study
The use of a combined outcome for LTF and death was
necessitated due to the high proportion of unrecorded deaths that
end up being defined as LTF, [3] but precluded the exploration of
each process separately. Although the completeness of viral load
results was similar between groups, the completeness was less than
would be anticipated based on guidelines, possibly reducing the
overall ascertainment of virologic rebound.
The majority of patients transitioning to club-based care were
already responding well to therapy and were assumed to be
adherent based on immunologic and virologic response. This
indication bias when comparing to patients remaining in routine
care was addressed in the analysis in two ways. First the analysis
was adjusted for the same variables considered by clinicians when
inviting patients to join a club, measured at the time that patients
first became eligible for the clubs. Secondly, through the inverse
probability weighting, any time varying confounding that might
result from changes in these parameters after study entry was
further adjusted for. Although simpler cohort analytical ap-
proaches showed similar benefits (as evidenced by the presented
unweighted models), the approach based on IPTW’s was preferred
due to the strong prior assumption that time-dependent con-
founding may be present. Assuming relevant associations with club
participation have been correctly measured and included in the
analysis, and there is no unmeasured confounding, the weighted
results should approximate those from a randomized comparison.
[20].
As with all observational studies, we cannot rule out in-
surmountable limitations, especially in adjusting for biases in who
accessed adherence clubs. There remains the possibility that
unmeasured patient-level factors such as openness to group-based
care, and willingness and motivation to participate in the clubs
could result in residual confounding. As described however, the
determination of who entered clubs and who did not was largely
the result of clinician practice and club availability rather than
patient preference overwhelmingly patients offered the club model
took up the option due to the perceived benefits. It remains
a limitation of the study however that refusals and which club
entries were patient-initiated were not recorded, and reasons for
refusal where present could have introduced unmeasured con-
founding.
This analysis equates to an intention-to-treat study as after first
entering a club, patients were considered to be in the club
treatment group until the end of the study. This is necessitated as
a return to clinic-based routine care is usually the result of clinical
or adherence problems, which would increase the event rates in
routine care if this follow-up time was apportioned to routine care,
and bias the analysis in favour of the club model.
Finally, we were unable to formally assess potential risks
associated with non-clinical care. While it is reassuring that
retention and adherence were likely improved by the club
participation, it is possible that some clinical diagnoses were
missed.
Future Research
Club availability has since been expanded and extended to all
clinics in the sub-district, enabling ongoing increases in enrolment
without additional clinical staff. Future operational research will
need to verify that adherence strategies based on patient groups
can be successfully adapted to the specific needs and character-
istics of different service and community settings. The manage-
ment of these groups is becoming increasingly challenging as the
number of groups associated with a single clinic increases,
requiring new management strategies and related research.
Groups are now meeting in the community, introducing
challenges in the delivery of pre-packaged drugs to community
settings, and the collection, transfer and review of patient and
program management data.
Conclusion
Patient adherence groups were found to be an effective model
for improving retention and documented virologic suppression for
stable adult patients in long term ART care in Khayelistha.
Models based on patient adherence groups meeting outside of
pressurized clinical consultation areas, and facilitated by non-
clinical staff, are a promising approach to assist in the next wave of
increased access to HIV treatment.
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